Concise review: mesenchymal stromal/stem cells: a new treatment for sepsis and septic shock?

C Laroye, S Gibot, L Reppel, D Bensoussan - Stem Cells, 2017 - academic.oup.com
C Laroye, S Gibot, L Reppel, D Bensoussan
Stem Cells, 2017academic.oup.com
Sepsis and septic shock are the leading cause of admission and mortality in non-coronary
intensive care units. Currently, however, no specific treatments are available for this
syndrome. Due to the failure of conventional treatments in recent years, research is focusing
on innovative therapeutic agents, including cell therapy. One particular type of cell,
mesenchymal stromal/stem cells (MSCs), has raised hopes for the treatment of sepsis.
Indeed, their immunomodulatory properties, antimicrobial activity and capacity of protection …
Abstract
Sepsis and septic shock are the leading cause of admission and mortality in non-coronary intensive care units. Currently, however, no specific treatments are available for this syndrome. Due to the failure of conventional treatments in recent years, research is focusing on innovative therapeutic agents, including cell therapy. One particular type of cell, mesenchymal stromal/stem cells (MSCs), has raised hopes for the treatment of sepsis. Indeed, their immunomodulatory properties, antimicrobial activity and capacity of protection against organ failure confer MSCs with a major advantage to treat the immune and inflammatory dysfunctions associated with sepsis and septic shock. After a brief description of the pathophysiology of sepsis and septic shock, the latest advances in the use of MSCs to treat sepsis will be presented.
Oxford University Press